Bank of America
PTGX icon

Bank of America’s Protagonist Therapeutics PTGX Stock Holding History

Bank of America’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,000
Closed -$2.18M – 8613
2025
Q1 		$2.18M Buy
+45,000
New +$1.89M ﹤0.01% 4607

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Bank of America's PTGX Position: Q1 2026 in Review

Bank of America increased its Protagonist Therapeutics (PTGX) stake by 49% in Q1 2026, buying an estimated $37.9M and bringing the position to 1,295,434 shares worth $137M. The position accounts for 0.01% of the portfolio, ranked #926.

Bank of America first reported a position in PTGX in Q4 2016 and has held it in 38 quarters since. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Bank of America held 1,295,434 shares of Protagonist Therapeutics worth $137M as of Q1 2026.
  • Bank of America bought 427,854 Protagonist Therapeutics shares in Q1 2026, an estimated $37.9M.
  • Protagonist Therapeutics made up 0.01% of Bank of America's portfolio in Q1 2026, its #926 holding.
  • Bank of America first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.